AEG 33783

Drug Profile

AEG 33783

Alternative Names: AEG33783

Latest Information Update: 15 Mar 2007

Price : $50

At a glance

  • Originator Aegera Therapeutics
  • Class Antineoplastics; Neuroprotectants
  • Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Diabetic neuropathies; Peripheral nervous system diseases

Most Recent Events

  • 15 Mar 2007 Discontinued - Preclinical for Diabetic neuropathies in Canada (IV)
  • 15 Mar 2007 Discontinued - Phase-I for Peripheral nervous system diseases in Canada (IV)
  • 15 Mar 2007 Discontinued - Preclinical for Cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top